Abstract
For many years alkylating agents especially chlorambucil had been considered drugs of choice for first-line treatment of progressive and symptomatic CLL. Subsequently, treatment approaches have included purine nucleoside analogs, fludarabine or cladribine, and monoclonal antibodies (mAb). Moreover, safety and efficacy of bendamustine were investigated in an open-label, randomized, comparative trial. In March 2008 bendamustine was approved by the USA FDA for the treatment of CLL. Recently, several new agents have been explored and have shown promise in treating CLL.These treatments include new mAbs, agents targeting the antiapoptotic bcl-2 family of proteins, receptors involved in mediating survival signals from the microenvironment, antisense oligonucleotides and other agents. The most promising are new mAbs targeted CD20 molecule, lumiliximab, apolizumab, galiximab and anti-CD40 mAbs. Oblimersen, flavopiridol, thalidomide and lenalidomide are also being evaluated both in pre-clinical studies and in early clinical trials.
Keywords: CLL, bendamustin, ofatumumab, GA-101, lumiliximab, galiximab, epratuzumab, flavopiridol, oblimersen, bryostatin 1
Current Cancer Therapy Reviews
Title: New Therapies for Patients with Chronic Lymphocytic Leukemia
Volume: 4 Issue: 4
Author(s): Tadeusz Robak and Pawel Robak
Affiliation:
Keywords: CLL, bendamustin, ofatumumab, GA-101, lumiliximab, galiximab, epratuzumab, flavopiridol, oblimersen, bryostatin 1
Abstract: For many years alkylating agents especially chlorambucil had been considered drugs of choice for first-line treatment of progressive and symptomatic CLL. Subsequently, treatment approaches have included purine nucleoside analogs, fludarabine or cladribine, and monoclonal antibodies (mAb). Moreover, safety and efficacy of bendamustine were investigated in an open-label, randomized, comparative trial. In March 2008 bendamustine was approved by the USA FDA for the treatment of CLL. Recently, several new agents have been explored and have shown promise in treating CLL.These treatments include new mAbs, agents targeting the antiapoptotic bcl-2 family of proteins, receptors involved in mediating survival signals from the microenvironment, antisense oligonucleotides and other agents. The most promising are new mAbs targeted CD20 molecule, lumiliximab, apolizumab, galiximab and anti-CD40 mAbs. Oblimersen, flavopiridol, thalidomide and lenalidomide are also being evaluated both in pre-clinical studies and in early clinical trials.
Export Options
About this article
Cite this article as:
Robak Tadeusz and Robak Pawel, New Therapies for Patients with Chronic Lymphocytic Leukemia, Current Cancer Therapy Reviews 2008; 4 (4) . https://dx.doi.org/10.2174/157339408786413380
DOI https://dx.doi.org/10.2174/157339408786413380 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Interventions Against Sarcopenia in Older Persons
Current Pharmaceutical Design Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Hemopressin Peptides as Modulators of the Endocannabinoid System and their Potential Applications as Therapeutic Tools
Protein & Peptide Letters Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus?
Current Vascular Pharmacology Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Immunosuppressive Therapies in Solid Organ Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) An Evidence-Based Systematic Review of Stevia by the Natural Standard Research Collaboration
Cardiovascular & Hematological Agents in Medicinal Chemistry Total Lipids and Fatty Acid Methyl Esters of Germinated Seeds of Mangrove Wild Legume
Current Nutrition & Food Science Mesoionic Oxatriazoles (MOTA): NO-Donating Characteristics and Pharmacology
Current Pharmaceutical Design Influence of Quaternary Conformation on the Biological Activities of the Asp49-phospholipases A2s from Snake Venoms
Protein & Peptide Letters Malformations of the Female Genital Tract and Embryological Bases
Current Women`s Health Reviews Arachidonate Cascade in the Intensive Insulin Therapy for Critically Ill Patients with Sepsis: Roles of Prostaglandins on Hyperglycemia-Impaired Immunity
Letters in Drug Design & Discovery Antisense Oligonucleotides in the Treatment of Cerebral Gliomas. Review of Concerning Patents
Recent Patents on CNS Drug Discovery (Discontinued) Role of CD14 in Host Response to Infection
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Antibacterial Effects of Carbon Monoxide
Current Pharmaceutical Biotechnology Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Proteases and their Receptors as Mediators of Inflammation-Associated Colon Cancer
Current Pharmaceutical Design Agonists and Antagonists of Protease Activated Receptors (PARs)
Current Medicinal Chemistry Adverse Reactions to Iodinated Contrast Media Administered at the Time of Endoscopic Retrograde Cholangiopancreatography (ERCP)
Inflammation & Allergy - Drug Targets (Discontinued) Oxidative Stress and Mitochondrial Dysfunction in Sepsis: A Potential Therapy with Mitochondria-Targeted Antioxidants
Infectious Disorders - Drug Targets